Search

Thanks to pioneering work done at MSK, a powerful new form of radiation therapy is changing the treatment of advanced cancers.

… Thursday, September 11, 2025 A high-intensity radiation beam that penetrates the body to burn away tumors has been a standard weapon against cancer for more than a century. Over the years, radiation therapy has improved dramatically, but its effectiveness against cancers in multiple places can be limited

Neoadjuvant relatlimab and nivolumab achieved high response rates with a favorable safety profile in patients with advanced melanoma, according to initial data from a small clinical trial conducted by researchers at Memorial Sloan Kettering Cancer Center (MSK) and the University of Texas MD Anderson Cancer Center (MD Anderson).

… Wednesday, December 7, 2022 Neoadjuvant relatlimab and nivolumab achieved high response rates with a favorable safety profile in patients with advanced melanoma, according to initial data from a small clinical trial conducted by researchers at Memorial Sloan Kettering Cancer Center (MSK) and the University

Learn about the goals of the Fiona and Stanley Druckenmiller Center for Lung Cancer Research: to reveal more about the biology of lung cancer, to examine novel treatment approaches, and to bring promising new therapies to our patients.

… Thursday, October 1, 2020 Lung cancer causes more deaths in the United States than colon, breast, and prostate cancers combined. Memorial Sloan Kettering launched the Fiona and Stanley Druckenmiller Center for Lung Cancer Research (DCLCR) in 2015 with three primary goals: to reveal more about the biology

Meet three people who were treated as part of a clinical trial for melanoma at Memorial Sloan Kettering.

… Wednesday, February 7, 2018 Summary Behind the incredible discoveries that happen in MSK labs are the equally incredible patients who walk through our doors and bring the science to life. Here, meet three MSK patients who took part in a clinical trial led by surgeon Charlotte Ariyan for the treatment

The global prize is awarded annually to a researcher, physician, or team leader who has made a positive and lasting impact in the fight against pediatric cancer.

… Thursday, May 20, 2021 Memorial Sloan Kettering Cancer Center (MSK) announced that pediatric oncologist A. Thomas Look, MD , of the Dana-Farber / Boston Children’s Cancer and Blood Disorder Center has been named the 2021 recipient of The Society of Memorial Sloan Kettering Prize . The award was presented

With founding partner Equinox, Cycle for Survival surpasses $285 million raised since 2007; every dollar funds rare cancer research led by Memorial Sloan Kettering Cancer Center.

… Monday, June 21, 2021 With founding partner Equinox, Cycle for Survival surpasses $285 million raised since 2007; every dollar funds rare cancer research led by Memorial Sloan Kettering Cancer Center. In the midst of a global pandemic, Cycle for Survival , the movement to beat rare cancers, raised $25

MSK investigators are leading the way with approaches so bold they are like the difference between "a snapshot and a movie."

… Friday, April 1, 2022 VIDEO | 00:25 A Developing Mouse Embryo This movie from the Kat Hadjantonakis lab shows an 11-day-old mouse embryo with its internal organs labeled in different fluorescence. The video was prepared by postdoc Evan Bardot. Video Details To study a complex ecosystem, researchers often

Learn about important advances in the treatment of pancreatic cancer.

… Thursday, June 5, 2025 Many people have questions about pancreatic cancer and its prognosis. MSK surgeon-scientist and pancreatic cancer expert Vinod Balachandran, MD, discusses why the disease is so hard to detect, what the latest treatment options are, and how promising research may improve survival

The Cycle for Survival community, along with founding partner, Equinox, achieves a historic fundraising milestone, fueling rare cancer research at Memorial Sloan Kettering.

… Thursday, April 28, 2022 Cycle for Survival, the movement to beat rare cancers, made history by surpassing $300 million in total funds raised through its signature stationary-cycling events. Since 2007, more than 1 million participants worldwide, including patients, caregivers, survivors, as well as

Learn how MSK uses the watch-and-wait approach to rectal cancer, which can preserve people's quality of life by successfully treating rectal cancer without removing the rectum.

… Friday, February 28, 2025 There’s an alternative for treating some patients with  rectal cancer that makes it possible to avoid  surgical removal of the rectum and the related side effects, which can include changes to sexual function and fertility and the possibility of a permanent ostomy bag — a pouch